GEODON PATENT EXPIRES ON March 2, 2012 !

Quote
















This patent is gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone IN SETEMBER 2012

bI BI AH
 




Anonymous said:
This patent is gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone gone IN SETEMBER 2012

bI BI AH
Click to expand...

Damn. Obviously the drug doesn't work as well as advertised, because you are still having MAJOR issues. Lobotomy time for you!
 








Pharmaceutical and biotechnology major Wockhardt has received tentative USFDA approval for marketing a generic version of 20 mg, 40 mg, 60 mg and 80 mg capsules containing Ziprasidone hydrochloride, which is used in the treatment of bipolar disorders and schizophrenia.

Ziprasidone capsule is the generic name for the brand Geodon, marketed in the US by Pfizer. Wockhardt will launch the product on Sept. 02, 2012. According to IMS Health, the total market for this product in the US is about USD 1.3 billion.
 




Anonymous said:
Pharmaceutical and biotechnology major Wockhardt has received tentative USFDA approval for marketing a generic version of 20 mg, 40 mg, 60 mg and 80 mg capsules containing Ziprasidone hydrochloride, which is used in the treatment of bipolar disorders and schizophrenia.

Ziprasidone capsule is the generic name for the brand Geodon, marketed in the US by Pfizer. Wockhardt will launch the product on Sept. 02, 2012. According to IMS Health, the total market for this product in the US is about USD 1.3 billion.
Click to expand...

Geodon is set to go bibi it will lose 1.3 billion revenues in a blink of an eye. This will be a very catautrofic loss for Pfizer who failed to produce a competitive schizophrenia pill. The revenue for Geodon will Canabalize in 3 flat months.
 




Anonymous said:
Geodon is set to go bibi it will lose 1.3 billion revenues in a blink of an eye. This will be a very catautrofic loss for Pfizer who failed to produce a competitive schizophrenia pill. The revenue for Geodon will Canabalize in 3 flat months.
Click to expand...

This nasty ass drugs patent is about to go splat

HaHahAHAHAHAAh pfizer you little girl buy buy money for you
 




Anonymous said:
Geodon is set to go bibi it will lose 1.3 billion revenues in a blink of an eye. This will be a very catautrofic loss for Pfizer who failed to produce a competitive schizophrenia pill. The revenue for Geodon will Canabalize in 3 flat months.
Click to expand...

Indian drug maker Wockhardt has received tentative approval from the Food and Drug Administration for a generic version of a Pfizer psychiatric drug.

Wockhardt announced the tentative approval for ziprasidone hydrochloride in the 20 mg, 40 mg, 60 mg and 80 mg strengths, used to treat bipolar disorder and schizophrenia, and the company plans to launch the drug on Sept. 2, 2012.

The drug is a generic version of Pfizer's Geodon, which has a market size of about $1.3 billion, according to IMS Health. Tentative approval means that the generic drug meets the conditions for FDA approval, but the agency can't approve it because the branded drug's patent has not yet expired. One of Geodon's patents expired in March 2012, and another expires on Sept. 1 of this year, while two more expire in 2018 and 2019, according to FDA records. The drug will lose data exclusivity in November 2012.
 












So I started with the company in 1991 and left in 2005. What a crazy spinout Pfizer has had! When we launched Trovan the company forecasted Pfizer would remain number one on its own accord but would strategically absorb strong companies
In the late 90s Karen Katen told us typing the human genome would bring targeted genetically driven with novel delivery systems by 2010. This would fuel the next phase of growth while current patents expired. Working with Roerig and in neuroscience I first hand saw the company give up on Geodon giving the salespeople no tools to sell with but put crazy amounts of pressure on reps to really do the impossible. I am surprised it hit a billion. Congrats reps! Thts quite a feat. You r all still using Stahl?! We came out of launch with tht paper
Thinking abt getting back into the field now. Any feedback ?
 




Top Bottom
Back
Quote